trial

Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia

NCTId NCT02197286
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by NYU Langone Health
Primary completion 2017-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-02
Primary completion
2017-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cholecalciferol

Sponsors

NYU Langone HealthLead Sponsor
Stanley Medical Research InstituteCollaborator
Columbia UniversityCollaborator

Investigators

1
James D ClellandPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia — primary completion2017-12

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2017-12
Status
WITHDRAWN
relationships
The graph out of here
drug
Cholecalciferol
drug
lead_sponsor
NYU Langone Health
company
collaborator
Stanley Medical Research Institute
company
Columbia University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
James D Clelland
person